Foresite Capital is a multi-stage healthcare and life sciences investment firm founded in 2011 by Jim Tananbaum. Headquartered in the San Francisco Bay Area, with additional offices in Los Angeles and New York City, the firm focuses on addressing significant unmet needs in healthcare by investing in promising businesses at all stages of their life cycles. Utilizing a data science-driven approach, Foresite Capital targets companies that leverage biology and big data to transform healthcare.

The firm's investment strategy emphasizes breakthrough opportunities at the intersection of technology and biotechnology, supported by a deeply technical investment team. As of June 2024, Foresite Capital has raised six primary funds, including Fund VI, which closed in May 2024 with $900 million in capital commitments. The firm's portfolio includes notable companies such as 10x Genomics, Element Biosciences, Lyell Immunopharma, Inscripta, Relay Therapeutics, and Gemini Therapeutics.

Foresite Capital's team offers comprehensive support to its portfolio companies, leveraging expertise in company formation, therapeutics product development, and data science/machine learning to provide strategic guidance and technical assistance.